Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N
Health Services Research Unit, University of Oxford, Institute of Health Sciences, Headington, UK.
Age Ageing. 1997 Sep;26(5):353-7. doi: 10.1093/ageing/26.5.353.
to briefly outline the development and validation of the Parkinson's Disease Questionnaire (PDQ-39) and then to provide evidence for the use of the measure as either a profile of health status scores or a single index figure.
the PDQ-39 was administered in two surveys: a postal survey of patients registered with local branches of the Parkinson's Disease Society of Great Britain (n = 405) and a survey of patients attending neurology clinics for treatment for Parkinson's disease (n = 146). Data from the eight dimensions of the PDQ-39 were factor-analysed. This produced a single factor on the data from both surveys.
the eight dimensions of the PDQ-39 and the new single index score-the Parkinson's disease summary index (PDSI), together with clinical assessments (the Columbia rating scale and the Hoehn and Yahr staging score).
in the postal survey 227 patients returned questionnaires (58.2%). AH 146 patients approached in the clinic sample agreed to take part. Higher-order principal-components factor analysis was undertaken on the eight dimensions of the PDQ-39 and produced one factor on both datasets. Consequently it was decided that the scores of the eight domains could be summed to produce a single index figure. The psychometric properties of this index were explored using reliability tests and tests of construct validity. The newly derived single index was found to be both internally reliable and valid.
data from the PDQ-39 can be presented either in profile form or as a single index figure. The profile should be of value in studies aimed at determining the impact of treatment regimes upon particular aspects of functioning and well-being in patients with Parkinson's disease, while the PDSI will provide a summary score of the impact of the illness on functioning and well-being and will be of use in the evaluation of the overall effect of different treatments. Furthermore, the PDSI reduces the number of statistical comparisons and hence the role of chance when exploring data from the PDQ-39.
简要概述帕金森病问卷（PDQ - 39）的编制与验证过程，然后为将该量表用作健康状况评分概况或单一指标数值提供依据。
在两项调查中使用了PDQ - 39：一项是对在英国帕金森病协会当地分会登记的患者进行的邮寄调查（n = 405），另一项是对前往神经科诊所接受帕金森病治疗的患者进行的调查（n = 146）。对PDQ - 39八个维度的数据进行了因子分析。两项调查的数据均得出了一个单一因子。
PDQ - 39的八个维度、新的单一指标得分——帕金森病综合指数（PDSI），以及临床评估指标（哥伦比亚评定量表和霍恩与雅尔分期评分）。
在邮寄调查中，227名患者返回了问卷（58.2%）。临床样本中接触的146名患者均同意参与。对PDQ - 39的八个维度进行了高阶主成分因子分析，两个数据集均得出了一个因子。因此，决定将八个领域的得分相加得出一个单一指标数值。使用信度测试和结构效度测试对该指数的心理测量特性进行了探究。发现新得出的单一指数在内部是可靠且有效的。
PDQ - 39的数据既可以以概况形式呈现，也可以作为单一指标数值呈现。该概况对于旨在确定治疗方案对帕金森病患者特定功能和健康方面影响的研究具有价值，而PDSI将提供疾病对功能和健康影响的综合评分，并将用于评估不同治疗的总体效果。此外，PDSI减少了统计比较的数量，从而在探索PDQ - 39数据时降低了偶然性的作用。
